Results 1 to 10 of about 7,553 (206)
Targeting Bruton’s Tyrosine Kinase in CLL [PDF]
Frontiers in Immunology, 2021 Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj +3 more sources
Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective [PDF]
Heliyon, 2023 Bruton's tyrosine kinase (BTK) is a protein involved in B-cell-receptor signaling and B-cell proliferation. The pathophysiology of several autoimmune diseases, such as pemphigus disorder, relies on the BTK signaling pathway.
Yekta Ghane +4 more
doaj +2 more sources
ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library. [PDF]
PLoS ONE, 2017 Bruton's Tyrosine Kinase (BTK) is a cytoplasmic protein tyrosine kinase with a fundamental role in B-lymphocyte development and activation. The nucleocytoplasmic shuttling of BTK is specifically modulated by the Ankyrin Repeat Domain 54 (ANKRD54) protein
Manuela O Gustafsson +8 more
doaj +7 more sources
Role of Bruton’s tyrosine kinase in B cells and malignancies [PDF]
Molecular Cancer, 2018 Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Simar Pal Singh +2 more
doaj +6 more sources
Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase. [PDF]
PLoS ONE, 2013 Diminished Ikaros function has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Therefore, a stringent regulation of Ikaros is of paramount importance for normal lymphocyte ontogeny ...
Hong Ma +5 more
doaj +4 more sources
Bruton's Tyrosine Kinase Inhibitors: Recent Updates. [PDF]
Int J Mol SciBruton’s tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders. The BTK receptor is expressed in several hematopoietic cells such as macrophages, neutrophils, mast cells, and osteoclasts.
Fares A +5 more
europepmc +3 more sources
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis [PDF]
Therapeutic Advances in Neurological DisordersBruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Laura Airas +8 more
doaj +2 more sources
Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors [PDF]
Frontiers in Immunology, 2021 C. I. Edvard Smith +3 more
doaj +3 more sources
PLoS ONE, 2023 Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Daichi Akasaka +9 more
doaj +2 more sources
Frontiers in Pharmacology, 2022 Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song +21 more
doaj +1 more source